Summary & Overview
HCPCS Q4314: Reeva per Square Centimeter Add-On Product
HCPCS Level II code Q4314 identifies the Reeva product billed per square centimeter as an add-on to a primary procedure. As an add-on HCPCS Level II code, Q4314 is used when a topical or localized treatment delivered by surface area supplements a separately reported primary service. This designation matters nationally because add-on supply and product codes affect how facilities and clinicians report adjunctive treatments and how payers adjudicate bundled versus separately payable items.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a succinct description of the code, the clinical and service context in which it is used, and guidance on what to expect in payer coverage assessment. The publication outlines common modifiers associated with this code, typical sites of service where the product is applied, and notes on coding practices relevant to add-on product reporting. The analysis also highlights areas where payers commonly differ in coverage and payment policies for add-on topical products and signals which elements clinicians and billing staff should verify with payers.
Data not available in the input is identified where necessary.
Billing Code Overview
HCPCS Level II code Q4314 describes Reeva ft, per square cenitmeter (add-on, list separately in addition to primary procedure). This code represents an add-on topical or localized treatment product billed by surface area and is intended to be reported in addition to a primary procedure when the Reeva product is applied.
Service type: Topical or localized treatment product administered per square centimeter as an add-on to a primary procedural service.
Typical site of service: Hospital outpatient departments, ambulatory surgical centers, physician offices, or other settings where the primary procedure is performed and an adjunct topical or local treatment is applied.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a localized chronic non-healing wound or soft-tissue defect (for example, a chronic neuropathic foot ulcer, venous stasis ulcer, or post-debridement surgical wound) requiring application of a biologic skin substitute product measured and billed per square centimeter. The clinical workflow begins with wound assessment, debridement and cleansing in an outpatient clinic, wound care center, or ambulatory surgical center. After achieving hemostasis and appropriate preparation of the wound bed, the clinician measures the defect in square centimeters, selects the Reeva biologic graft sized to the defect, and applies the product to the wound with appropriate fixation (sutures, staples, surgical adhesive, or dressing). Documentation includes wound dimensions, indication for placement, product name and lot number, number of square centimeters applied, concurrent procedures (for example, debridement, dressings, or closure), and provider performing the procedure. Typical sites of service include outpatient wound care clinics, physician offices, hospital outpatient departments, and ambulatory surgical centers. Typical patient scenario: a 62-year-old patient with diabetes mellitus and peripheral neuropathy presents with a 4.5 cm2 plantar foot ulcer present for 8 weeks despite standard wound care; after sharp debridement and infection control, a biologic skin substitute is applied and billed using Q4314 per square centimeter as an add-on to the primary procedure.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |